Localization of Transforming Growth Factor Alpha and Its Receptor in Gastric Mucosal Cells

Total Page:16

File Type:pdf, Size:1020Kb

Localization of Transforming Growth Factor Alpha and Its Receptor in Gastric Mucosal Cells Localization of transforming growth factor alpha and its receptor in gastric mucosal cells. Implications for a regulatory role in acid secretion and mucosal renewal. R D Beauchamp, … , J A Cherner, R J Coffey Jr J Clin Invest. 1989;84(3):1017-1023. https://doi.org/10.1172/JCI114223. Research Article Transforming growth factor alpha (TGF alpha) shares with epidermal growth factor (EGF) structural homology (35%), a common cell-surface membrane receptor (TGF alpha/EGF receptor), and a nearly identical spectrum of biological activity, including inhibition of gastric acid secretion. Herein, we report expression of TGF alpha mRNA in normal gastric mucosa of the adult guinea pig, rat, and dog. TGF alpha mRNA was also detected in matched surgically resected gastric mucosa and adjacent gastric carcinoma from 10 patients, and in gastric mucosa adjacent to a benign ulcer from an additional patient. TGF alpha protein was quantitated by radioimmunoassay and was present in tumor and adjacent mucosa. TGF alpha/EGF receptor mRNA was also detected in gastric mucosa from all species studied. Localization of TGF alpha and TGF alpha/EGF receptor mRNA expression was examined in samples of unfractionated guinea pig gastric mucosa and from chief cell-enriched and parietal cell-enriched fractions. All samples exhibited TGF alpha and TGF alpha/EGF receptor expression. The TGF alpha signal was greatest in the parietal cell fraction (5.8-fold increase), but was also enhanced in the chief cell fraction (1.9-fold increase) relative to the unfractionated gastric mucosa. Like TGF alpha expression, TGF alpha/EGF receptor mRNA expression was most intense in the parietal cell-enriched fraction (7.8-fold increase), but was also increased in the chief cell-enriched fraction (2.7-fold increase) relative to the unfractionated […] Find the latest version: https://jci.me/114223/pdf Localization of Transforming Growth Factor a and Its Receptor in Gastric Mucosal Cells Implications for a Regulatory Role in Acid Secretion and Mucosal Renewal R. D. Beauchamp,** J. A. Bamard,*9 C. M. McCutchen,11 J. A. Chemer,11 and R. J. Coffey, Jr.*,' *Departments ofCell Biology, $Surgery, §Pediatrics, and IIMedicine, Vanderbilt University School ofMedicine, Nashville, Tennessee 37232 Abstract pression has been detected in a number of nontransformed cells and tissues (7-9). The spectrum of biological activity for Transforming growth factor a (TGFa) shares with epidermal TGFa and EGF are qualitatively similar, although several growth factor (EGF) structural homology (35%), a common quantitative differences have been observed (10, 1 1). All cell-surface membrane receptor (TGFa/EGF receptor), and a known actions of both ligands appear to be mediated via bind- nearly identical spectrum of biological activity, including inhi- ing to the TGFa/EGF receptor; no discrete TGFa receptor has bition of gastric acid secretion. Herein, we report expression of been identified (12). TGFa mRNA in normal gastric mucosa of the adult guinea pig, Both EGF and TGFa have been shown to have potent rat, and dog. TGFa mRNA was also detected in matched sur- effects on the gastric mucosa, a complex epithelium composed gically resected gastric mucosa and adjacent gastric carcinoma of multiple cell types. Surface epithelial cells, which line the from 10 patients, and in gastric mucosa adjacent to a benign mucosa of all regions of the stomach, secrete mucus and bi- ulcer from an additional patient. TGFa protein was quantitated carbonate. Parietal cells, which secrete hydrochloric acid, and by radioimmunoassay and was present in tumor and adjacent chief cells, which secrete pepsinogen, are found primarily in mucosa. TGFa/EGF receptor mRNA was also detected in gastric glands in the fundus and body. Neuroendocrine cells gastric mucosa from all species studied. Localization of TGFa consist of gastrin-producing G-cells, somatostatin-producing and TGFa/EGF receptor mRNA expression was examined in D-cells, enterochromaffin cells and enterochromaffin-like samples of unfractionated guinea pig gastric mucosa and from cells; their distribution varies with the particular cell type, e.g., chief cell-enriched and parietal cell-enriched fractions. All the stomach's G-cells are confined to the antrum (13). samples exhibited TGFa and TGFa/EGF receptor expression. EGF stimulates DNA synthesis in the gastric mucosa of The TGFa signal was greatest in the parietal cell fraction rodents (14-16) and protects against gastric ulcer formation in (5.8-fold increase), but was also enhanced in the chief cell have no effect on acid secretion gas- rats and cats at doses that ( 16). fraction (1.9-fold increase) relative to the unfractionated Removal of salivary glands (the major intraluminal source of tric mucosa. Like TGFa expression, TGFa/EGF receptor in rats results in of mucosa and a mRNA expression was most intense in the parietal cell- EGF) atrophy gastric (17) delay in healing of gastric and duodenal ulcerations that can be enriched fraction (7.8-fold increase), but was also increased in reversed by treating the animals with either oral or parenteral the chief cell-enriched fraction (2.7-fold increase) relative to EGF (18). These studies imply an important physiological role the unfractionated guinea pig gastric mucosa. We conclude in Of in that and for EGF gastric mucosal growth. potential importance TGFa TGFa/EGF receptor genes are expressed in TGFa and EGF are acid stable normal adult mammalian gastric mucosa. These findings, when the stomach, both (19) (20) in TGFa and EGF, proteins. interpreted light of described actions of Extracts from human urine have long been known to in- provide evidence that local production of TGFa could play an acid secretion The acid role in the and mucosal hibit gastric (21, 22). putative gastric important regulation of acid secretion inhibitory agent was named urogastrone. Subsequent purifica- renewal in the stomach. tion and characterization of human EGF (20, 21) and human Introduction f3-urogastrone (24) revealed that they were identical. In con- scious dogs, EGF inhibits gastric acid secretion stimulated by Epidermal growth factor (EGF)' and transforming growth pentagastrin, histamine, and urecholine, as well as that stimu- factor a (TGFa) are homologous polypeptides (1, 2), both of lated by meal and sham feeding (25). In anesthetized rats, EGF which bind to the EGF receptor (3-5). TGFa was initially inhibits gastric acid secretion stimulated by carbachol, hista- postulated to be an embryonic growth factor that was inappro- mine, and pentagastrin (26). EGF (27) and TGFa (28) inhibit priately expressed in neoplasia (6). More recently, TGFa ex- histamine-stimulated gastric acid secretion from isolated guinea pig gastric mucosa when delivered to the serosal, but Address reprint requests to Dr. Coffey, Jr., Department of Medicine, not luminal surface; intravenous delivery of both ligands in- Gastroenterology Division, Vanderbilt University, Nashville, TN hibits acid secretion in rats (29). In addition to inhibiting acid 37232. secretion, EGF inhibits pepsinogen secretion in rabbit gastric Received for publication 8 November 1988 and in revised form 4 mucosa stimulated by agonists that increase intracellular May 1989. cAMP (30). High affinity TGFa/EGF binding sites have been 1. Abbreviations used in this paper: EGF, epidermal growth factor; demonstrated on both fundic and antral gastric glands from TGFa, transforming growth factor a. the guinea pig (31). TGFa is no longer regarded simply as an embryonic J. Clin. Invest. growth factor that is inappropriately expressed in neoplasia, © The American Society for Clinical Investigation, Inc. but also as an integral physiological regulator of growth in 3021-9738/89/09/1017/07 $2.00 normal tissues ( 12, 32, 33). In screening gastrointestinal tissues Volume 84, September 1989, 1017-1023 for TGFa expression, we found relatively abundant levels in Transforming Growth Factor a in the Stomach 1017 the gastric mucosa. Given the aforementioned effects of TGFa RNA was quantitated by ultraviolet spectroscopy at 260 nM. Relative and EGF on gastric mucosal growth, repair, and acid secretion, loading of lanes and the integrity of RNA was verified by ethidium we examined gastric mucosa from four mammalian species for bromide-stained ribosomal RNA band intensity where precise quanti- TGFa, EGF, and TGFa/EGF receptor expression and at- tation was necessary. Laser densitometry was performed for quantita- tempted to localize expression to a subpopulation of gastric tion of 28S ribosomal RNA on a photographic negative of gels and for mucosal signal intensity on autoradiograms of Northern blots. cells. Protein extraction for TGFa. Extraction of gastric mucosal TGFa protein was performed using a modification of a previously described Methods method (19). One to two grams of previously frozen (-80°C) human gastric mucosa or carcinoma was homogenized and stirred overnight at Processing oftissue. Gastric mucosa was obtained from normal adult 4°C in 4 ml/g of acid-ethanol solution containing 90% ethanol, 0.2 M mongrel dogs, guinea pigs, and rats at sacrifice and kidneys were ob- HCI, pepstatin (5 Mg/ml), leupeptin (5 gg/ml), and PMSF (0.5 mM). tained from rats and dogs. Human gastric and kidney samples were The homogenate was clarified by centrifugation and the supernatant obtained fresh from the Department of Surgical Pathology. Human stored while the pellet was resuspended and stirred 4 h at 4°C in a gastric carcinoma and adjacent uninvolved gastric mucosa were also second acid-ethanol solution containing 77% ethanol and 0.2 M HCI, obtained from the Cooperative Human Tissue Network of the Na- after which the suspension was centrifuged. Both supernatants were tional Cancer Institute and from the Mayo Clinic (Rochester, MN). then combined, extensively dialyzed using Spectrapor 3 dialysis tubing The gastric mucosa was washed with cold water and then rapidly (3,500 mol wt cut-off) against 0.1 M acetic acid, and lyophilized. dissected from the muscularis. The samples were rapidly frozen in Before the TGFa assay, the extracts were resuspended in a minimal liquid nitrogen and stored at -80°C until processing.
Recommended publications
  • ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are The
    0031-3998/07/6103-0267 PEDIATRIC RESEARCH Vol. 61, No. 3, 2007 Copyright © 2007 International Pediatric Research Foundation, Inc. Printed in U.S.A. ARTICLES Fibroblast Growth Factors 1, 2, 17, and 19 Are the Predominant FGF Ligands Expressed in Human Fetal Growth Plate Cartilage PAVEL KREJCI, DEBORAH KRAKOW, PERTCHOUI B. MEKIKIAN, AND WILLIAM R. WILCOX Medical Genetics Institute [P.K., D.K., P.B.M., W.R.W.], Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Obstetrics and Gynecology [D.K.] and Department of Pediatrics [W.R.W.], UCLA School of Medicine, Los Angeles, California 90095 ABSTRACT: Fibroblast growth factors (FGF) regulate bone growth, (G380R) or TD (K650E) mutations (4–6). When expressed at but their expression in human cartilage is unclear. Here, we deter- physiologic levels, FGFR3-G380R required, like its wild-type mined the expression of entire FGF family in human fetal growth counterpart, ligand for activation (7). Similarly, in vitro cul- plate cartilage. Using reverse transcriptase PCR, the transcripts for tivated human TD chondrocytes as well as chondrocytes FGF1, 2, 5, 8–14, 16–19, and 21 were found. However, only FGF1, isolated from Fgfr3-K644M mice had an identical time course 2, 17, and 19 were detectable at the protein level. By immunohisto- of Fgfr3 activation compared with wild-type chondrocytes and chemistry, FGF17 and 19 were uniformly expressed within the showed no receptor activation in the absence of ligand (8,9). growth plate. In contrast, FGF1 was found only in proliferating and hypertrophic chondrocytes whereas FGF2 localized predominantly to Despite the importance of the FGF ligand for activation of the resting and proliferating cartilage.
    [Show full text]
  • Supplementary Table 1
    Supplementary table 1 List of the 92 proteins analyzed in the multiplex proximity extension assay (PEA) Long name (short name) UniProt No. LOD (pg/mL) Adenosine Deaminase (ADA) P00813 0.48 Artemin (ARTN) Q5T4W7 0.24 Axin-1 (AXIN1) O15169 61,0 Beta-nerve growth factor (Beta-NGF) P01138 0.48 Brain-derived neutrophic factor (BDNF) P23560 Caspase 8 (CASP-8) Q14790 0.48 C-C motif chemokine 4 (CCL4) P13236 1.9 C-C motif chemokine 19 (CCL19) Q99731 15,0 C-C motif chemokine 20 (CCL20) P78556 7.6 C-C motif chemokine 23 (CCL23) P55773 31,0 C-C motif chemokine 25 (CCL25) O15444 3.8 C-C motif chemokine 28 (CCL28) Q9NRJ3 61,0 CD40L receptor (CD40) P25942 0.01 CUB domain-containing protein 1 (CDCP1) Q9H5V8 0.12 C-X-C motif chemokine 1 (CXCL1) P09341 3.8 C-X-C motif chemokine 5 (CXCL5) P42830 0.95 C-X-C motif chemokine 6 (CXCL6) P80162 7.6 C-X-C motif chemokine 9 (CXCL9) Q07325 0.95 C-X-C motif chemokine 10 (CXCL10) P02778 7.6 C-X-C motif chemokine 11 (CXCL11) O14625 7.6 Cystatin D (CST5) P28325 1.9 Delta and Notch-like epidermal growth factor related receptor (DNER) Q8NFT8 0.95 Eotaxin-1 (CCL11) P51671 3.8 Eukaryotic translation initiation factor 4E-binding protein 1 (4EBP1) Q13541 Fibroblast growth factor 5 (FGF-5) Q8NF90 1.9 Fibroblast growth factor 19 (FGF-19) O95750 7.6 Fibroblast growth factor 21 (FGF-21) Q9NSA1 31,0 Fibroblast growth factor 23 (FGF-23) Q9GZV9 122,0 Fms-related tyrosine kinase 3 ligand (FIt3L) P49771 0.01 Fractalkine (CX3CL1) P78423 15.3 Glial cell line-derived neutrophic factor (hGDNF) P39905 0.01 Hepatocyte growth factor (HGF)
    [Show full text]
  • Artificial Liver Support Potential to Retard Regeneration?
    REVIEW ARTICLE Artificial Liver Support Potential to Retard Regeneration? Emma J. Mullin, MBChB; Matthew S. Metcalfe, FRCS; Guy J. Maddern, MD Hypothesis: The concept of an “artificial liver” has been growth-promoting factors from these cultured hepato- in development for over 40 years. Such devices aim to cytes? temporarily assume metabolic and excretory functions of the liver, with removal of potentially hepatotoxic sub- Data Sources, Extraction, and Study Selection: stances, thereby clinically stabilizing patients and pre- Data were obtained using PubMed search for reports in- venting deterioration while awaiting transplantation. If volving liver support, extracorporeal circuits, dialysis, sufficient numbers of viable hepatocytes remain, regen- growth factors, and cytokines. Those reports specifi- eration and subsequent recovery of innate liver func- cally looking at the effect of artificial liver support on cy- tion may occur. However, these devices have not yet be- tokines and growth factors are discussed. come part of routine clinical use. Much less is known regarding the effect such devices have, if any, on circu- Conclusions: There is a paucity of information on the lating cytokines and growth factors and the subsequent key events and substances involved in hepatic regenera- effects on the regenerating liver. If these devices remove tion. In addition, there is a potential impact of liver sup- or reduce factors known to promote regeneration, is the port devices on the regeneration of substances associ- rate of regeneration retarded? Conversely, does the in- ated with hepatic regeneration. Further study is needed. corporation of hepatocytes into bioartificial support sys- tems confer an advantage through the production of Arch Surg.
    [Show full text]
  • And Insulin-Like Growth Factor-I (IGF-I) in Regulating Human Erythropoiesis
    Leukemia (1998) 12, 371–381 1998 Stockton Press All rights reserved 0887-6924/98 $12.00 The role of insulin (INS) and insulin-like growth factor-I (IGF-I) in regulating human erythropoiesis. Studies in vitro under serum-free conditions – comparison to other cytokines and growth factors J Ratajczak, Q Zhang, E Pertusini, BS Wojczyk, MA Wasik and MZ Ratajczak Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA, USA The role of insulin (INS), and insulin-like growth factor-I (IGF- has been difficult to assess. The fact that EpO alone fails to I) in the regulation of human erythropoiesis is not completely stimulate BFU-E in serum-free conditions, but does do in understood. To address this issue we employed several comp- lementary strategies including: serum free cloning of CD34؉ serum containing cultures indicates that serum contains some cells, RT-PCR, FACS analysis, and mRNA perturbation with oli- crucial growth factors necessary for the BFU-E development. godeoxynucleotides (ODN). In a serum-free culture model, both In previous studies from our laboratory, we examined the ؉ INS and IGF-I enhanced survival of CD34 cells, but neither of role of IGF-I12 and KL9,11,13 in the regulation of early human these growth factors stimulated their proliferation. The influ- erythropoiesis. Both of these growth factors are considered to ence of INS and IGF-I on erythroid colony development was be crucial for the BFU-E growth.3,6,8,14 Unexpectedly, that dependent on a combination of growth factors used for stimul- + ating BFU-E growth.
    [Show full text]
  • Human TGF Alpha ELISA Kit Basic Information: Catalog No.: UE1330 Size: 96T for Research Use Only
    Efficient Professional Protein and Antibody Platforms Human TGF alpha ELISA Kit Basic information: Catalog No.: UE1330 Size: 96T For research use only. Not for diagnostic or therapeutic procedures. I. INTRODUCTION Transforming growth factor alpha (TGF-α) is upregulated in some human cancers. It is produced in macrophages, brain cells, and keratinocytes, and induces epithelial development. It is closely related to EGF, and can also bind to the EGF receptor with similar effects . TGFα stimulates neural cell proliferation in the adult injured brain. Transforming growth factor alpha gene (TGFA) maps to human chromosome 2 close to the breakpoint of the t (2;8) variant translocation in Burkitt lymphoma. Synthetic TGF-alpha was as active as murine epidermal growth factor in binding to the epidermal growth factor receptor and in stimulation of anchorage-dependent and of anchorage-independent growth of normal indicator cells in culture. Synthetic TGF-alpha stimulated plasminogen activator production in A 431 and HeLa cells; the stimulation was similar to that induced by epidermal growth factor. Furthermore, synthetic human TGF-alpha showed similar immunoreactivity when compared with rat TGF-alpha. Thus, the 50-amino acid TGF-alpha is likely to be the bioactive principle produced and secreted by tumor cell lines. II. ASSAY PRINCIPLES The Gene Universal Human TGF alpha ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of Human TGF alpha in Cell Culture Supernatants, Serum, Plasma. This assay employs an antibody specific for Human TGF alpha coated on a 96-well plate. Standards and samples are pipetted into the wells and TGF alpha present in a sample is bound to the wells by the immobilized antibody.
    [Show full text]
  • Growth Hormone Enhances Hepatic Epidermal Growth Factor Receptor Concentration in Mice
    Growth hormone enhances hepatic epidermal growth factor receptor concentration in mice. J O Jansson, … , W G Beamer, L A Frohman J Clin Invest. 1988;82(6):1871-1876. https://doi.org/10.1172/JCI113804. Research Article The effect of growth hormone (GH) on binding of epidermal growth factor (EGF) to liver membrane preparations was investigated in hypophysectomized mice and partially GH-deficient, genetic mutant "little" (lit/lit) mice. The EGF binding of normal male mice and testosterone-treated females was higher than in normal females. Due to diminished receptor concentration, hepatic EGF binding was decreased in male and female lit/lit mice to a level that was unaffected by gender or androgen treatment. GH replacement therapy by intermittent injections and continuous infusion restored the EGF binding of hypophysectomized mice to normal male and female levels, respectively, suggesting a role for the more pulsatile GH secretion in normal males. In lit/lit mice, however, both continuous and intermittent GH resulted in EGF binding levels comparable to those in normal females. In normal males continuous GH suppressed EGF binding. In conclusion, endogenous GH secretion induces EGF receptors in mice and this effect may be modulated by sex differences in GH secretion. Find the latest version: https://jci.me/113804/pdf Growth Hormone Enhances Hepatic Epidermal Growth Factor Receptor Concentration in Mice John-Olov Jansson,** Staffan Ekberg,t Steven B. Hoath,* Wesley G. Beamer," and Lawrence A. Frohman* Divisions of*Endocrinology and ONeonatology, University of Cincinnati College ofMedicine, Cincinnati, Ohio 45267; "Jackson Laboratory, Bar Harbor, Maine 04609; and tDepartment ofPhysiology, University ofGoteborg, Sweden Abstract (IGF-I), which may function in a paracrine and autocrine as well as endocrine manner (6-8).
    [Show full text]
  • Proseek Multiplex Oncology I V296×96
    Proseek Multiplex Oncology I v296×96 Adrenomedullin (AM) P35318 Fms-related tyrosine kinase 3 ligand (Flt3L) P49771 Amphiregulin (AR) P15514 Folate receptor alpha (FR-alpha) P15328 Angiopoietin-1 receptor (TIE2) Q02763 Follistatin (FS) P19883 B-cell activating factor (BAFF) Q9Y275 Furin (FUR) P09958 Cadherin-3 (CDH3) P22223 Growth hormone (GH) P01241 Carbonic anhydrase IX (CAIX) Q16790 Growth/differentiation factor 15 (GDF-15) Q99988 Carcinoembryonic antigen (CEA) P06731 Heparin-binding EGF-like growth factor (HB-EGF) Q99075 Caspase-3 (CASP-3) P42574 Hepatocyte growth factor (HGF) P14210 C-C motif chemokine 19 (CCL19) Q99731 ICOS ligand (ICOSLG) O75144 CD40 ligand (CD40-L) P29965 Immunoglobulin-like transcript 3 (ILT-3) Q8NHJ6 C-X-C motif chemokine 5 (CXCL5 ) P42830 Integrin alpha-1 (ITGA1) P56199 C-X-C motif chemokine 9 (CXCL9 ) Q07325 Interferon gamma (IFN-gamma) P01579 C-X-C motif chemokine 10 (CXCL10 ) P02778 Interleukin-1 receptor antagonist protein (IL-1ra) P18510 C-X-C motif chemokine 11 (CXCL11 ) O14625 Interleukin-2 (IL-2) P60568 C-X-C motif chemokine 13 (CXCL13 ) O43927 Interleukin-6 (IL-6) P05231 Cyclin-dependent kinase inhibitor 1 (CDKN1A) P38936 Interleukin-6 receptor subunit alpha (IL-6RA) P08887 Cystatin-B (CSTB) P04080 Interleukin-7 (IL-7) P13232 Early activation antigen CD69 (CD69 ) Q07108 Interleukin-8 (IL-8) P10145 Epidermal growth factor receptor (EGFR ) P00533 Interleukin-12 (IL-12) P29460; P29459 Epididymal secretory protein E4 (HE4 ) Q14508 Interleukin-17 receptor B (IL-17RB ) Q9NRM6 Epithelial cell adhesion molecule
    [Show full text]
  • The Endometrial Lymphatic Vasculature: Function and Dysfunction
    The Endometrial Lymphatic Vasculature: Function and Dysfunction Jane E. Girling and Peter A.W. Rogers Gynaecology Research Centre, Department of Obstetrics and Gynaecology, The University of Melbourne, Melbourne, Victoria 3052, Australia. Corresponding Author: Dr Jane E Girling Gynaecology Research Centre Department of Obstetrics and Gynaecology The University of Melbourne The Royal Women’s Hospital Cnr Flemington Rd and Grattan St Parkville, VIC 3058, Australia Email: [email protected] Telephone: +61 3 8345 3721 Fax: +61 3 8345 3702 1 Abstract The endometrium has a complex and dynamic blood and lymphatic vasculature which undergoes regular cycles of growth and breakdown. While we now have a detailed picture of the endometrial blood vasculature, our understanding of the lymphatic vasculature in the endometrium is limited. Recent studies have illustrated that the endometrium contains a population of lymphatic vessels with restricted distribution in the functional layer relative to the basal layer. The mechanisms responsible for this restricted distribution and the consequences for endometrial function are not known. This review will summarise our current understanding of endometrial lymphatics, including the mechanisms regulating their growth and function. The potential contribution of lymphatic vessels and lymphangiogenic growth factors to various endometrial disorders will be discussed. Keywords: Blood Vessels, Decidua, Endometrium, Lymphatics, Menstruation, VEGFC, VEGFD 2 1. Introduction The endometrium has a complex and dynamic blood and lymphatic vasculature which undergoes regular cycles of growth and breakdown. These cyclic changes reflect variations in circulating sex steroids and uterine blood flow and result in cyclic patterns in tissue oxygenation, haemostasis, nutrient supply, fluid balance and leukocyte distribution. Appropriate growth and functioning of the vasculature is essential for normal endometrial function, including preparation for potential embryo implantation and subsequent pregnancy.
    [Show full text]
  • Factor-The Controlling Growth Factor-At a Sufficiently Low Value, While the Cell Population Has Ceased to Grow and Is in a Sort
    708 GENETICS: NO VICK A ND SZILARD PROC. N. A. S. EXPERIMENTS WITH THE CHEMOSTAT ON SPONTANEOUS MUTATIONS OF BACTERIA By AARON NOVICK AND LEO SZILARD INSTITUTRE OF RADIOBIOLOGY AND BIOPHYSICS, UNIVERSITY OF CHICAGO Communicated by H. J. Muller, October 18, 1950 Introduction.-All bacteria require for growth the presence of certain inorganic chemical components in the nutrient, such as potassium, phos- phorus, sulphur, etc., and with a few exceptions all bacteria require an energy-yielding carbon source, such as, for instance, glucose or lactate, etc. In addition to these elements or simple compounds, certain bacteria require more complex compounds, for instance an amino acid, which they are not capable of synthesizing. For the purposes of this presentation, any of the chemical compounds which a given strain of bacteria requires for its growth will be called a "growth factor." In general, the growth rate of a bacterial strain may be within very wide limits independent of the concentration of a given growth factor; but since at zero concentration the growth rate is zero, there must of necessity exist, at sufficiently low concentrations of the growth factor, a region in which the growth rate falls with falling concentration of the growth factor. It therefore should be possible to maintain a bacterial population over an indefinite period of time growing at a rate considerably lower than normal simply by maintaining the concentration of one growth factor-the controlling growth factor-at a sufficiently low value, while the concentrations of all other growth factors may at the same time be main- tained at high values.
    [Show full text]
  • Canine TGF-Alpha ELISA Kit
    Canine TGF-alpha ELISA Kit Catalog #: AYQ-E10339 (96 wells) User Manual This kit is designed to quantitatively detect the levels of Canine TGF-alpha in cell lysates, serum/ plasma and other suitable sample solution. Manufactured and Distributed by: AssaySolution 310 W Cummings Park, Woburn, MA, 01801, USA Phone: (617) 238-1396, Fax: (617) 380-0053 Email: [email protected] FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC PURPOSES Important notes Before using this product, please read this manual carefully; after reading the subsequent contents of this manual, please note the following specially: • The operation should be carried out in strict accordance with the provided instructions. • Store the unused strips in a sealed foil bag at 2-8°C. • Always avoid foaming when mixing or reconstituting protein solutions. • Pipette reagents and samples into the center of each well, avoid bubbles. • The samples should be transferred into the assay wells within 15 minutes of dilution. • We recommend that all standards, testing samples are tested in duplicate. • Using serial diluted sample is recommended for first test to get the best dilution factor. • If the blue color develops too light after 15 minutes incubation with the substrate, it may be appropriate to extend the incubation time (Do not over-develop). • Avoid cross-contamination by changing tips, using separate reservoirs for each reagent. • Avoid using the suction head without extensive wash. • Do not mix the reagents from different batches. • Stop Solution should be added in the same order of the Substrate Solution. • TMB developing agent is light-sensitive. Avoid prolonged exposure to the light.
    [Show full text]
  • Involvement of Vascular Endothelial Growth Factor Signaling in CLR/RAMP1 and CLR/RAMP2-Mediated Pro-Angiogenic Effect of Interme
    289-294.qxd 18/6/2010 08:32 Ì ™ÂÏ›‰·289 INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 26: 289-294, 2010 289 Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intermedin on human vascular endothelial cells GIOVANNA ALBERTIN, ELISA SORATO, BARBARA OSELLADORE, ALESSANDRA MASCARIN, CINZIA TORTORELLA and DIEGO GUIDOLIN Department of Human Anatomy and Physiology, Section of Anatomy, University of Padova-Medical School, I-35121 Padova, Italy Received January 27, 2010; Accepted March 30, 2010 DOI: 10.3892/ijmm_00000464 Abstract. Intermedin (IMD) is a recently discovered peptide initiation and propagation by transactivating the VEGF closely related to adrenomedullin. Its principal physiological receptor-2 machinery. activity is its role in the regulation of the cardiovascular system, where it exerts a potent hypotensive effect. In addition, Introduction data were recently provided showing that this peptide is able to exert a clearcut pro-angiogenic effect both in vitro and In early 2004, a novel member of the calcitonin (CT)/calcitonin- in vivo. IMD acts through the non-selective interaction with gene related peptide (CGRP) family was independently receptor complexes formed by the dimerization of calcitonin- identified by two separate groups. Roh and colleagues (1) like receptor (CLR) with the receptor activity-modifying discovered the human form of this peptide in cells within the proteins RAMP1, 2 or 3. Thus, in the present study, the role of intermediate lobe of the pituitary and called it intermedin (IMD). CLR/RAMP complexes in mediating the pro-angiogenic effect At the same time, Takei et al (2) identified in mammals a 146- induced by IMD on human umbilical vein endothelial cells 150 amino acid prepro-hormone which yielded to a 47-amino (HUVECs) cultured on Matrigel was examined.
    [Show full text]
  • Updated November 2019 KIT Mutation the KIT Gene Is Associated With
    Updated November 2019 KIT Mutation The KIT gene is associated with autosomal dominant piebaldism, gastrointestinal stromal tumors (GISTs), and familial mastocytosis.1-3 The type of mutation identified in the KIT gene determines the symptoms/cancer risks that the individual may have. Pathogenic loss-of-function (LOF) mutations in the KIT gene are generally only associated with Piebaldism. However, pathogenic gain of function mutations in the KIT gene are associated with systemic mastocytosis and gastrointestinal stromal tumors.4,5 Piebaldism: This is a rare condition characterized by the patchy absence of melanocytes in certain areas of the skin and hair. Melanocytes produce the pigment melanin, which contributes to hair, eye, and skin color. The absence of melanocytes leads to patches of skin and hair that are lighter than normal. These unpigmented areas are typically present at birth and do not increase in size or number.6-8 Gastrointestinal stromal tumors (GIST): GISTs are tumors that occur in the gastrointestinal tract, most commonly in the stomach or small intestine. Small tumors may cause no signs or symptoms. However, some people with GISTs may experience pain or swelling in the abdomen, nausea, vomiting, loss of appetite, or weight loss. These tumors can be cancerous (malignant) or noncancerous (benign). Mastocytosis: This is a blood disorder that occurs when white blood cells called mast cells accumulate in one or more tissues (most commonly in the bone marrow). Mast cells normally trigger inflammation during an allergic reaction. When an environmental trigger activates mast cells, they release proteins that signal an immune response. In systemic mastocytosis, excess mast cells mean more proteins are being released in the tissues where the cells accumulate, leading to an increased immune response.
    [Show full text]